Skip to main content

Kevzara News

FDA Approves Kevzara (sarilumab) for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)

  TARRYTOWN, N.Y. and CAMBRIDGE, MA, June 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration has approve...

Sarilumab Beneficial for Polymyalgia Rheumatica Patients

THURSDAY, Oct. 5, 2023 – For patients with polymyalgia rheumatica with relapse during tapering of glucocorticoid therapy, treatment with sarilumab, the human monoclonal antibody that binds to the...

Kevzara (sarilumab) Approved by FDA as First and Only Biologic Indicated for Patients with Polymyalgia Rheumatica

Cambridge, MA and Tarrytown, N.Y. February 28, 2023. The U.S. Food and Drug Administration (FDA) has approved Kevzara® (sarilumab) for the treatment of polymyalgia rheumatica (PMR), an inflammatory ...

Sanofi and Regeneron Announce FDA Approval of Kevzara (sarilumab) for Rheumatoid Arthritis

PARIS and TARRYTOWN, N.Y., May 22, 2017 /PRNewswire/ – Sanofi and Regeneron Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) approval of Kevzara (sarilumab) for the...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Polymyalgia Rheumatica, Rheumatoid Arthritis

Kevzara patient information at Drugs.com